AGM/EGMApr 27, 2026, 04:13 PM
DFTX to Hold AGM on June 11; Proposes 5M Share Equity Plan Increase
AI Summary
Definium Therapeutics, Inc. will hold its Annual General and Special Meeting of Shareholders virtually on June 11, 2026, at 10:00 a.m. ET. Shareholders will vote on the election of seven directors, the appointment of KPMG LLP as the independent auditor, and an amendment to the 2025 Equity Incentive Plan to increase available common shares by 5,000,000. The company also highlighted recent progress in clinical trials for DT120 ODT and DT402, a $259 million equity financing, and leadership team enhancements.
Key Highlights
- Shareholders to vote on 7 director nominees at June 11, 2026 AGM.
- Proposal to increase 2025 Equity Incentive Plan shares by 5,000,000.
- KPMG LLP proposed for appointment as independent auditor.
- Full enrollment achieved in Phase 3 Emerge (MDD) and Voyage (GAD) studies.
- Secured $259 million in gross proceeds from Q4 2025 equity financing.
- Appointed new CFO and CCO in 2025; added Roger Adsett to Board in 2026.
- Phase 2a trial of DT402 in ASD initiated in Q4 2025.